Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Sup-plementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice

• Main Authors: F Zamani Sorkhroodi, AM Alavi Naeini, AR Zahraei Ramazani, MR Aghaye Ghazvini, M Mohebali, SA Keshavarz
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2010-09-01
• Series: Iranian Journal of Parasitology
• Subjects: Leishmania major; Sodium selenite; Zinc sulphate; Meglumine Antimoniate (glucantime®); BALB/c
• Online Access: https://ijpa.tums.ac.ir/index.php/ijpa/article/view/141

Background: Successful therapy of leishmaniasis depends on effective cellular immune response. We evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in combination with Glucantime® in treatment of cutaneous leishmaniasis lesions resulting from Leishmania ma­jor in susceptible animal model. Methods: Thirty three female mice weighing 18-20 g at the age of 7-8 week infected with L. major were randomly divided into 3 groups: group1:  treated by sodium selenite (0.35 mg/kg for 30 days), group2: treated by zinc sulphate (2 mg/kg for 30 days) and group3: treated by distilled water (0.01 ml/gr body weight for 30 days) as control. All groups received Glucantime® as a standard anti- leishmanial agent (60 mg/kg, ip) for 14 days. To assess the results of treatment measurement of lesions size and parasitological tests were done weekly. Results: The lesion sizes increased continuously in sodium selenite group .Although, in zinc group did not in­crease compared to baseline But with considering the time- group interaction there was no significant difference between zinc and control group during this study.  There was no difference between lesion sizes and Leishmanial loads in the interventional and control groups, respectively. Conclusion: Sodium selenite and zinc sulphate at mentioned doses and duration of treatment did not show any treatment effect on cutaneous leishmaniasis caused by L. major in BALB/c mice. Increasing the dose of supplements and considering the follow up period after treatment can help more certain conclusion.